Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer

Microscaled proteogenomics was deployed to probe the molecular basis for differential response to neoadjuvant carboplatin and docetaxel combination chemotherapy for triple-negative breast cancer (TNBC). Proteomic analyses of pretreatment patient biopsies uniquely revealed metabolic pathways, includi...

Descripción completa

Detalles Bibliográficos
Autores principales: Anurag, Meenakshi, Jaehnig, Eric J., Krug, Karsten, Lei, Jonathan T., Bergstrom, Erik J., Kim, Beom-Jun, Vashist, Tanmayi D., Huynh, Anh Minh Tran, Dou, Yongchao, Gou, Xuxu, Huang, Chen, Shi, Zhiao, Wen, Bo, Korchina, Viktoriya, Gibbs, Richard A., Muzny, Donna M., Doddapaneni, Harshavardhan, Dobrolecki, Lacey E., Rodriguez, Henry, Robles, Ana I., Hiltke, Tara, Lewis, Michael T., Nangia, Julie R., Nemati Shafaee, Maryam, Li, Shunqiang, Hagemann, Ian S., Hoog, Jeremy, Lim, Bora, Osborne, C. Kent, Mani, D.R., Gillette, Michael A., Zhang, Bing, Echeverria, Gloria V., Miles, George, Rimawi, Mothaffar F., Carr, Steven A., Ademuyiwa, Foluso O., Satpathy, Shankha, Ellis, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627136/
https://www.ncbi.nlm.nih.gov/pubmed/36001024
http://dx.doi.org/10.1158/2159-8290.CD-22-0200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627136/
https://www.ncbi.nlm.nih.gov/pubmed/36001024
http://dx.doi.org/10.1158/2159-8290.CD-22-0200

Ejemplares similares